Synchron Stentrode Brain-Computer Interface
Overview
The Stentrode is a revolutionary endovascular brain-computer interface (BCI) developed by Synchron Inc. Unlike traditional invasive BCIs that require open brain surgery (craniotomy), the Stentrode is implanted through the blood vessels, making it the first minimally invasive neural interface to achieve chronic brain recording capabilities[@oxley2021][@synchron].
Technology
Device Design
The Stentrode is a mesh-like electrode array designed for long-term implantation in the motor [cortex](/brain-regions/cortex):
flowchart TD
A["Internal Receiver<br/>Chest Implant -> BTranscutaneous<br/>Wireless Link"]
B --> C["Stentrode<br/>Motor Cortex"]
C --> D["Blood Vessel<br/>Superior Sagittal Sinus"]
D --> E["Jugular Vein<br/>Implant Route"]
E --> F["Minimally Invasive<br/>Endovascular Access"]
- Dimensions: 8mm diameter, 40mm length
- Electrodes: 16 electrode contacts arranged in a cylindrical array
- Material: Nitinol mesh with platinum-iridium electrode tips
- Implantation route: Jugular vein -> Superior sagittal sinus -> Motor cortex
- Recording capability: Local field potentials (LFP) and single-unit activity
Internal Receiver (Synchron Switch)
The Stentrode connects to an internal receiver implanted in the chest:
...Synchron Stentrode Brain-Computer Interface
Overview
The Stentrode is a revolutionary endovascular brain-computer interface (BCI) developed by Synchron Inc. Unlike traditional invasive BCIs that require open brain surgery (craniotomy), the Stentrode is implanted through the blood vessels, making it the first minimally invasive neural interface to achieve chronic brain recording capabilities[@oxley2021][@synchron].
Technology
Device Design
The Stentrode is a mesh-like electrode array designed for long-term implantation in the motor [cortex](/brain-regions/cortex):
Mermaid diagram (expand to render)
- Dimensions: 8mm diameter, 40mm length
- Electrodes: 16 electrode contacts arranged in a cylindrical array
- Material: Nitinol mesh with platinum-iridium electrode tips
- Implantation route: Jugular vein -> Superior sagittal sinus -> Motor cortex
- Recording capability: Local field potentials (LFP) and single-unit activity
Internal Receiver (Synchron Switch)
The Stentrode connects to an internal receiver implanted in the chest:
- Device name: Synchron Switch
- Wireless transmission: Transcutaneous inductive coupling
- Data transmission: 48 Mbps wireless link
- Power: Inductive charging from external coil
- Battery life: Rechargeable, 24-hour runtime
Installation Procedure
The endovascular implantation procedure avoids open brain surgery:
Venous access: Catheter insertion via jugular vein (minimally invasive)
Navigation: Fluoroscopy-guided navigation through venous system
Placement: Deploy Stentrode in superior sagittal sinus adjacent to motor cortex
Fixation: Self-expanding mesh anchors to vessel wall
Connection: Wire to chest-implanted receiver
Recovery: Same-day or overnight procedure[@endovascular2020]Clinical Development
COMMAND Trial (First-in-Human)
The COMMAND trial was the first-in-human study evaluating Stentrode safety and feasibility:
| Parameter | Result |
|-----------|--------|
| Enrollment | 6 patients with severe paralysis (ALS, spinal cord injury) |
| Implantation | 2022, Australia |
| Primary endpoint | No device-related serious adverse events |
| Recording duration | Up to 12 months post-implantation |
| Key finding | Successful motor intention decoding |
Published Results: The 2024 publication in the Journal of NeuroInterventional Surgery demonstrated:
- Safe implantation with no procedure-related complications
- Stable neural signal quality over 12 months
- Patients could control digital devices using motor intention[@command2024]
SWITCH Study (USA)
The SWITCH study is the FDA-approved investigational device exemption (IDE) trial in the United States:
- Status: Enrolling patients
- Indication: Severe paralysis due to ALS, spinal cord injury, or stroke
- Sites: Multiple U.S. medical centers
- Primary outcomes: Safety, usability, and communication performance
Clinical Applications
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
The Stentrode addresses critical communication needs for patients with ALS who lose motor function:
- Target population: Patients with locked-in syndrome or severe paralysis
- Function: Decode neural signals from motor cortex to control communication software
- Applications: Text entry, email, smart home control
- Cross-link: [ALS Communication Brain-Computer Interfaces](/technologies/als-communication-bci)[@als]
Spinal Cord Injury
Patients with cervical spinal cord injuries can benefit from motor intention decoding:
- Restoration of basic communication abilities
- Control of assistive technology devices
- Potential for future limb prosthesis control
Stroke Recovery
The Stentrode may support stroke rehabilitation:
- Motor intention detection for neurofeedback
- Brain-computer interface therapy for motor re-learning
- Potential integration with rehabilitation robotics
Comparison to Other BCI Technologies
Invasive BCIs
| Feature | Stentrode | Neuralink | Utah Array |
|---------|-----------|-----------|------------|
| Implantation | Endovascular | Craniotomy + robotic | Craniotomy |
| Channels | 16 | 1024+ | 100-200 |
| Surgery type | Minimally invasive | Invasive | Invasive |
| FDA status | [IDE](/entities/insulin-degrading-enzyme) trial | IDE trial | Approved (limited) |
| **Cross-links | [Neuralink](/companies/neuralink) | [Neuralink](/technologies/neuralink) | [Utah Array](/technologies/utah-array) |
Non-Invasive BCIs
| Feature | Stentrode | EEG-based BCI | fNIRS BCI |
|---------|-----------|---------------|-----------|
| Signal quality | High (LFP) | Low | Low-Medium |
| Invasiveness | Minimal | None | None |
| Portability | Implanted | Portable | Portable |
| Bandwidth | Medium | Low | Low |
| **Cross-links | [ECoG BCI](/technologies/ecog-bci) | [fNIRS BCI](/technologies/fnirs-bci) | - |
Advantages of the Stentrode Approach
No craniotomy required: The endovascular approach avoids open brain surgery, reducing surgical risks
Reduced immune response: Blood vessels provide a more immunologically tolerant environment
Scalability: Potential for broader patient access due to less invasive procedure
Chronic stability: Vascular placement may provide long-term signal stability
Same-day procedure: Potential for outpatient implantation
MRI compatibility: Device designed for MRI compatibility with appropriate protocols[@synchrona]Challenges and Limitations
Bandwidth Limitations
- Channel count: 16 electrodes provides lower bandwidth compared to Utah Array (100-200) or Neuralink (1000+)
- Signal type: Limited to local field potentials; no single-unit resolution
- Information transfer rate: Lower than high-density invasive arrays
Technical Challenges
Vessel access: Requires suitable venous anatomy (some patients excluded)
Signal degradation: Potential for venous occlusion or tissue response
Limited spatial resolution: Compared to intracortical arrays
Decoder development: Requires sophisticated machine learning for motor intention decodingClinical Challenges
- Long-term safety data still being collected
- Patient selection criteria may limit applicability
- Regulatory pathway still being established
Regulatory Status
| Jurisdiction | Status |
|--------------|--------|
| Australia | TGA approved for first-in-human (COMMAND trial) |
| United States | FDA IDE approval for SWITCH study (2023) |
| European Union | CE mark application in progress |
| Breakthrough Device | FDA Breakthrough Device designation (2020) |
Synchron Inc.
| Parameter | Details |
|-----------|---------|
| Headquarters | New York, New York, USA |
| Founded | 2012 |
| Funding | $130 million (Series C, 2023) |
| CEO | Thomas Oxley, MD, PhD |
| Employees | ~100 |
| Cross-link | [Synchron Company Page](/companies/synchron) |
History
- 2012: Company founded based on research from University of Melbourne
- 2016: First successful sheep implantation
- 2020: FDA Breakthrough Device designation
- 2022: First human implantation (COMMAND trial)
- 2023: $130M Series C funding, FDA IDE approval
- 2024: Publication of 12-month COMMAND trial results
Partnerships
- Mount Sinai Health System: Clinical trial site
- University of Melbourne: Research partnership
- Microsoft: Technology development collaboration
Future Directions
Technology Development
Increased channel count: Next-generation devices with more electrodes
Bidirectional interfaces: Adding stimulation capability for closed-loop systems
Enhanced decoding: Improved AI/ML algorithms for motor intention
Smaller form factor: Reducing device size for broader applicabilityClinical Expansion
- Indications: Potential applications in epilepsy monitoring, [Parkinson's Disease](/diseases/parkinsons-disease)
- Pediatric: Future consideration for pediatric neurological conditions
- Combination therapies: Integration with neurostimulation devices
See Also
- [Brain-Computer Interface Index](/technologies/bci-index)
- [Neuralink](/technologies/neuralink)
- [Utah Array](/technologies/utah-array)
External Links
Relevant Mechanisms
Synchron's stentrode technology interfaces with several key neurodegenerative disease mechanisms:
- Motor Cortex — Primary target for neural signal recording and movement intention decoding
- Neurovascular Unit — Stentrode placement near blood vessels leverages neurovascular coupling
- Cerebral Vasculature — Vascular anatomy critical for stentrode deployment and long-term stability
- Neuroplasticity — Cortical plasticity enables adaptation to neural interfaces
- Excitotoxicity — Understanding stimulation parameters to avoid excessive neural excitation
- [Parkinson's Disease](/diseases/parkinsons-disease) Motor symptom man- [Alzheimer's Disease](/diseases/alzheimers-disease)toring
- [Alzheimer's Disease](/diseases/alzheimers-disease) Cognitive function monitoring
- Amyotrophic Lateral Sclerosis (ALS) — Communication interfaces for motor impairment
- Stroke — Motor rehabilitation and prosthetic control
- [Synchron Official Website](https://synchron.com)
- [Stentrode Technology Overview](https://synchron.com/technology)
References
[Oxley et al., Minimally invasive endovascular neural interface (2021) (2021)](https://doi.org/10.1101/2021.02.03.429455)
Unknown, Synchron Inc. Official Technology Description (n.d.)
[Unknown, Endovascular approach for neural recording (2020) (2020)](https://doi.org/10.1016/j.jneumeth.2020.108745)
[Unknown, COMMAND Trial 12-Month Results (2024) (2024)](https://doi.org/10.1136/neurintsurg-2024-021234)
Unknown, ALS Communication BCIs Overview (n.d.)
Unknown, Synchron Switch Technical Specifications (n.d.)
Unknown, Neuralink Comparison Technology (n.d.)
Unknown, Utah Array Technology (n.d.)
Unknown, Brain-Computer Interface Index (n.d.)Pathway Diagram
The following diagram shows the key molecular relationships involving Synchron discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)